 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
.png){kind=logo} | |
| Company type | Public |
|---|---|
| Founded | 2010 |
| Founders |
|
| Headquarters | Cambridge, Massachusetts, U.S.; Beijing, China; Basel, Switzerland[1] |
| Revenue |  US$2.459 billion (2023) |
 US$−1.21 billion (2023) | |
| US$−882 million (2023) | |
| Total assets |  US$5.805 billion (2023) |
| Total equity | US$3.537 billion (2023) |
Number of employees | 10,600 (2024) |
| Website | www |
| Footnotes / references [2] | |
BeiGene, Ltd. is a China-based drug developer.[3] It specializes in the development of drugs for cancer treatment.[4] Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has offices in North America, Europe, South America, Asia and Australia.[5][6][7][8] BeiGene has a large presence in the Chinese market.[9] BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November, 2024 the company announced its intention to rebrand as BeOne Medicines.[10]
- ^ "Meet the most innovative and inventive pharmaceutical companies of 2021". Fortune. 16 April 2021. Archived from the original on 16 April 2021. Retrieved 21 June 2021.
- ^ "2023 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. 26 February 2024.
- ^ Leo, Leroy (14 July 2022). "FDA delays decision on BeiGene's cancer drug on China COVID curbs". Reuters.
- ^ Liu, Angus (29 April 2022). "BeiGene CEO touts 'strategic asset' in flagship US site and a fix to stock delisting risk". FiercePharma.
- ^ "BeiGene Expands Presence in Latin America With Opening of Brazil Office – BeiGene LTD". hkexir.beigene.com. Retrieved 28 March 2024.
- ^ "BeiGene expanding presence in Latin America". www.thepharmaletter.com. Retrieved 28 March 2024.
- ^ MEA, Channel 360 (26 October 2023). "BeiGene establishes UAE office to expand MENA operations". Channel 360 MEA. Retrieved 28 March 2024.
{{cite web}}: CS1 maint: numeric names: authors list (link) - ^ Flannery, Russell. "BeiGene Expects To Finish Construction At $700 Million New Jersey Site In 2024". Forbes. Retrieved 28 March 2024.
- ^ Beasley, Deena (October 31, 2019) Amgen takes 20.5% stake in BeiGene to sell cancer drugs in China Reuters
- ^ "BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer". www.businesswire.com. Retrieved 14 November 2024.